Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders
Joint Authors
Saletu, Bernd
Garg, Amit
Shoeb, Ahsan
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-08-27
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Nicergoline is a semisynthetic ergot derivative and has a selective alpha-1A adrenergic receptor blocking property and also other additional mechanisms of actions, both in the brain and in the periphery.
It is in clinical use for over three decades in over fifty countries for conditions such as cerebral infarction, acute and chronic peripheral circulation disorders, vascular dementia, and Alzheimer’s disease and has been found to be beneficial in a variety of other conditions.
However, concerns about its safety have been raised, especially after the European medicines agency’s (EMEA’s) restriction in the use of all ergot derivatives including nicergoline.
But, most of the available literature and data suggest that the adverse events with nicergoline are mild and transient.
Further, none of the available treatment options for cognitive disorders afford definitive resolution of symptoms.
In this backdrop, we discuss the pharmacology of nicergoline with special emphasis on the safety of this compound, especially when used in patients suffering from cognitive function disorders.
American Psychological Association (APA)
Saletu, Bernd& Garg, Amit& Shoeb, Ahsan. 2014. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. BioMed Research International،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1016392
Modern Language Association (MLA)
Saletu, Bernd…[et al.]. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. BioMed Research International No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1016392
American Medical Association (AMA)
Saletu, Bernd& Garg, Amit& Shoeb, Ahsan. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1016392
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1016392